Literature DB >> 8180026

Metabolism of ifosfamide during a 3 day infusion.

J M Hartley1, L Hansen, S J Harland, P W Nicholson, F Pasini, R L Souhami.   

Abstract

Urinary drug metabolites were measured in 21 patients receiving ifosfamide by continuous infusion over 3 days. Mean values for the proportion of drug excreted as parent compound, 2-dechloroethylifosfamide (2-DC), 3-dechloroethylifosfamide (3-DC), carboxyifosfamide (CX) and ifosforamide mustard (IPM) were 19, 6, 10, 7 and 8% of dose respectively. The proportion of urinary drug products in the form of ifosfamide fell considerably over the course of the 3 days. This was mirrored by an increase in the proportion of 2-DC, 3-DC and CX. The proportion in the form of IPM, however, remained unchanged. With successive cycles the amount of 2-DC and IPM increased by about 10% per course. A very wide variation in the amount of each metabolite was reproducibly seen between patients, but no evidence for a genetic polymorphism was found. Urinary dechloroethyl metabolites correlated positively with each other and negatively with CX. Although autoinduction increases 'activation' of ifosfamide when given over 3 days, our evidence suggests that competing metabolic pathways prevent an increase in the amount of active metabolite formed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180026      PMCID: PMC1968912          DOI: 10.1038/bjc.1994.180

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Pharmacokinetics of divided-dose ifosfamide.

Authors:  R L Nelson; L M Allen; P J Creaven
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

Review 3.  Metabolism of oxazaphosphorines.

Authors:  N E Sladek
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

4.  Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.

Authors:  R A Alarcon; J Meienhofer; E Atherton
Journal:  Cancer Res       Date:  1972-11       Impact factor: 12.701

5.  Dechloroethylation of ifosfamide and neurotoxicity.

Authors:  M P Goren; R K Wright; C B Pratt; F E Pell
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

6.  Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

Authors:  N Brock; J Pohl; J Stekar
Journal:  Eur J Cancer Clin Oncol       Date:  1981-11

7.  Pharmacokinetic studies in lung cancer patients.

Authors:  E Piazza; M T Cattaneo; M Varini
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

8.  Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.

Authors:  A V Boddy; S M Yule; R Wyllie; L Price; A D Pearson; J R Idle
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

9.  Pharmacokinetics and bioavailability of oral ifosfamide.

Authors:  T Wagner; P Drings
Journal:  Arzneimittelforschung       Date:  1986-05

10.  Studies on the metabolism of isopnosphamide (NSC-109724) in man.

Authors:  K Norpoth
Journal:  Cancer Treat Rep       Date:  1976-04
View more
  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

3.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

4.  The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.

Authors:  J M Singer; J M Hartley; C Brennan; P W Nicholson; R L Souhami
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.